Literature DB >> 24111929

Exercise endurance in chronic obstructive pulmonary disease patients at an altitude of 2640 meters breathing air and oxygen (FIO2 28% and 35%): a randomized crossover trial.

Dario Maldonado1, Mauricio González-García, Margarita Barrero, Claudia Jaramillo, Alejandro Casas.   

Abstract

BACKGROUND: At Bogota's altitude (2640 m), the lower barometric pressure (560 mmHg) causes severe hypoxemia in COPD patients, limiting their exercise capacity. The aim was to compare the effects of breathing oxygen on exercise tolerance.
METHODS: In a blind, crossover clinical study, 29 COPD patients (FEV1 42.9 ± 11.9%) breathed room air (RA) or oxygen (FIO2 28% and 35%) during three treadmill exercise tests at 70% of their maximal capacity in a randomized order. Endurance time (ET), inspiratory capacity (IC), arterial blood gases and lactate were compared.
RESULTS: At the end of the exercise breathing RA, the ET was 9.7 ± 4.2 min, the PaO2 46.5 ± 8.2 mmHg, the lactate increased and the IC decreased. The oxygen significantly increased the ET (p < 0.001), without differences between 28% (16.4 ± 6.8 min) and 35% (17.6 ± 7.0 min) (p = 0.22). Breathing oxygen, there was an increase in the PaO2 and SaO2, higher with FIO2 35%, and a decrease in the lactate level. At "isotime" (ET at RA), with oxygen, the SpO2, the oxygen pulse and the IC were higher and the heart rate lower than breathing RA (p < 0.05).
CONCLUSION: Oxygen administration for COPD patients in Bogotá significantly increased ET by decreased respiratory load, improved cardiovascular performance and oxygen transport. The higher increases of the PaO2 and SaO2 with 35% FIO2 did not represent a significant advantage in the ET. This finding has important logistic and economic implications for oxygen use in rehabilitation programs of COPD patients at the altitude of Bogotá and similar altitudes.

Entities:  

Keywords:  altitude; chronic obstructive pulmonary disease; endurance; exercise tolerance; hypoxemia; oxygen therapy

Mesh:

Substances:

Year:  2013        PMID: 24111929     DOI: 10.3109/15412555.2013.836480

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  5 in total

1.  Effect of Nocturnal Oxygen Therapy on Nocturnal Hypoxemia and Sleep Apnea Among Patients With Chronic Obstructive Pulmonary Disease Traveling to 2048 Meters: A Randomized Clinical Trial.

Authors:  Lu Tan; Tsogyal D Latshang; Sayaka S Aeschbacher; Fabienne Huber; Deborah Flueck; Mona Lichtblau; Stefanie Ulrich; Elisabeth D Hasler; Philipp M Scheiwiller; Silvia Ulrich; Konrad E Bloch; Michael Furian
Journal:  JAMA Netw Open       Date:  2020-06-01

2.  Effect of nocturnal oxygen therapy on exercise performance of COPD patients at 2048 m: data from a randomized clinical trial.

Authors:  Sophia Gutweniger; Tsogyal D Latshang; Sayaka S Aeschbacher; Fabienne Huber; Deborah Flueck; Mona Lichtblau; Stefanie Ulrich; Elisabeth D Hasler; Philipp M Scheiwiller; Silvia Ulrich; Konrad E Bloch; Michael Furian
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

3.  Comorbidities of Patients With Idiopathic Pulmonary Fibrosis in Four Latin American Countries. Are There Differences by Country and Altitude?

Authors:  Mauricio Gonzalez-Garcia; Emily Rincon-Alvarez; Maria Laura Alberti; Mauricio Duran; Fabian Caro; Maria Del Carmen Venero; Yuri Edison Liberato; Ivette Buendia-Roldan
Journal:  Front Med (Lausanne)       Date:  2021-06-17

4.  Exercise Capacity, Ventilatory Response, and Gas Exchange in COPD Patients With Mild to Severe Obstruction Residing at High Altitude.

Authors:  Mauricio Gonzalez-Garcia; Margarita Barrero; Dario Maldonado
Journal:  Front Physiol       Date:  2021-06-18       Impact factor: 4.566

5.  A Pervasive Healthcare System for COPD Patients.

Authors:  Hicham Ajami; Hamid Mcheick; Karam Mustapha
Journal:  Diagnostics (Basel)       Date:  2019-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.